Sign In
Buy ELDN
$3.81
-0.110 (-2.81%)
At Close: Jun 22, 2026
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
04:01pm, Thursday, 20'th Mar 2025
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positi
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
04:05pm, Tuesday, 04'th Mar 2025
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Wednesday, 29'th Jan 2025
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
11:27am, Tuesday, 28'th Jan 2025
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transpl
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
07:00am, Monday, 13'th Jan 2025
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updat
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
04:01pm, Tuesday, 12'th Nov 2024
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
03:51pm, Tuesday, 29'th Oct 2024
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, u
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
07:46am, Tuesday, 29'th Oct 2024
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its c
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose cont
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
04:05pm, Wednesday, 11'th Sep 2024
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
05:21pm, Wednesday, 14'th Aug 2024
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment)
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
07:00am, Monday, 29'th Jul 2024
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW tr
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
04:05pm, Tuesday, 02'nd Jul 2024
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company's management team will be hosting one-on-one meetings at
